NM_001037582.3(SCD5):c.642G>C (p.Glu214Asp) AND not specified

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Feb 7, 2023
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV004266148.1

Allele description [Variation Report for NM_001037582.3(SCD5):c.642G>C (p.Glu214Asp)]

NM_001037582.3(SCD5):c.642G>C (p.Glu214Asp)

Gene:

SCD5:stearoyl-CoA desaturase 5 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

4q21.22

Genomic location:

Preferred name:

NM_001037582.3(SCD5):c.642G>C (p.Glu214Asp)

HGVS:

NC_000004.12:g.82636751C>G
NM_001037582.3:c.642G>CMANE SELECT
NP_001032671.2:p.Glu214Asp
NC_000004.11:g.83557904C>G
NM_001037582.2:c.642G>C

Protein change:

E214D

Molecular consequence:

NM_001037582.3:c.642G>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:: AllHighlyPenetrant
Identifiers:: MedGen: CN169374

Recent activity

Clear Turn Off Turn On

602522[BioProject] (70853)
Nucleotide
RecName: Full=C-glycoside 3-oxidase; AltName: Full=MtCarA
RecName: Full=C-glycoside 3-oxidase; AltName: Full=MtCarA
gi|2813870812|sp|A0A0M2HFA3.1|CGLYO R

Protein
PREDICTED: Varanus komodoensis solute carrier family 39 member 3 (SLC39A3), tran...
PREDICTED: Varanus komodoensis solute carrier family 39 member 3 (SLC39A3), transcript variant X4, mRNA
gi|2118041511|ref|XM_044419103.1|

Nucleotide
Chain L, Cytochrome c oxidase subunit 7C, mitochondrial
Chain L, Cytochrome c oxidase subunit 7C, mitochondrial
gi|2069592686|pdb|7EV7|L

Protein
(("clinical guidelines"[Resource Type]) OR "practice guideline"[P... (6)
(("clinical guidelines"[Resource Type]) OR "practice guideline"[Publication Type]) AND ("Rectum mucinous adenocarcinoma")
Search

Books

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV003898847	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Feb 7, 2023)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV003898847

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Feb 7, 2023)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV003898847.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The c.642G>C (p.E214D) alteration is located in exon 4 (coding exon 4) of the SCD5 gene. This alteration results from a G to C substitution at nucleotide position 642, causing the glutamic acid (E) at amino acid position 214 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Nov 10, 2024

ClinVar

Relating variation to medicine